Unichem Laboratories Limited

BSE: 506690 NSE: UNICHEMLAB
Unichem Laboratories Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L99999MH1962PLC012451 Incorporated 22 August 1962 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: UNICHEMLAB · BSE: 506690 Public Limited Company pharma
Data last updated
Market Cap
₹3,551 Cr
UNICHEMLAB · NSE
Share Price
₹504.65
+0.05% today
Revenue
₹2,202 Cr
FY 2025-26 · +4.3% YoY
EBITDA
₹111 Cr
Margin 5.0%
Net Profit
₹81.89 Cr
FY 2025-26 · -40.1% YoY
P/E (TTM)
29.4x
P/B 1.3x
ROE
3.2%
ROCE 4.1%
Debt / Equity
0.19
Interest cover -216.2x

About Unichem Laboratories Limited

Data last updated:

Unichem Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 22 August 1962 and has been in existence for over 64 years.

Its director Prakash Amrut Mody is #1,113 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L99999MH1962PLC012451. Its GSTIN is 27AAACU0551B1ZW (Maharashtra). The company holds 26 GST registrations, of which 6 are active. Its shares are listed on BSE: 506690 and NSE: UNICHEMLAB.

The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹14.08 Cr. It is led by directors including Pabitrakumar Kalipada Bhattacharyya (Managing Director) and Prakash Amrut Mody.

Its last annual general meeting (AGM) was held on 04 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 47 Kandivli Industrial Estate, Mumbai, Maharashtra, India – 400067.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,201.85 Cr, a growth of 4.3% compared to the previous year. For the same year it recorded a net profit of ₹81.89 Cr (net margin 3.7%) and EBITDA of ₹110.51 Cr (EBITDA margin 5%). The net worth stands at ₹2,717.44 Cr (up 10.9% YoY). Total assets are valued at ₹3,246.65 Cr (up 10% YoY).

The company has about 3,635 employees on its provident fund (EPFO) records.

The company is associated with 2 brands: Unichem Laboratories and Unichem Labs. As per MCA filings, the company has open charges of ₹236 Cr and satisfied charges of ₹249.07 Cr on record. Court records list 245 cases involving the company, including 156 filed by the company and 72 filed against it; 40 cases are pending. The company has 14 deals on record (9 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹56.32 Cr; the latest was in July 2026. Its 10 peer companies in the Pharma industry (API Manufacturers, Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Aarti Drugs Limited with revenue of ₹2,403.39 Cr. The company has 30 MSME Form 1 returns on record between 2014 and 2024, listing 197 overdue payments to 63 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website unichemlabs.com.

Company Details of Unichem Laboratories Limited
CIN L99999MH1962PLC012451
Registration Number 012451
Incorporation Date 22 August 1962
ROC Mumbai
Listing Status Listed (BSE: 506690, NSE: UNICHEMLAB)
Company Status Active
Date of Last AGM 04 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Pabitrakumar Kalipada Bhattacharyya Managing Director Prakash Amrut Mody Director Swati Arvind Patankar Additional Director

Recognitions & Rankings of Unichem Laboratories

India's Richest People 2026 edition · 1 director · Source: Hurun India
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    unichemlabs.com
  • Social Media
  • Registered Address
    47 Kandivli Industrial Estate, Mumbai, Maharashtra, India – 400067
  • Industry
    Pharma, API Manufacturers, Drug Formulation & Development
Comprehensive company report
Unichem Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Unichem Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Unichem Laboratories Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Associated Brands with Unichem Laboratories Limited

Unichem Laboratories operates two associated brands: Unichem Laboratories and Unichem Labs. Each brand links to its own profile.

BrandDescriptionWebsite
Unichem Labs
Branded formulations, APIs, and biosimilars are manufactured.unichemlabs.com
Unichem Laboratories
Pharmaceutical formulations, active pharmaceutical ingredients manufacturing, and related services in India.unichem-hrp.com

Business Activity of Unichem Laboratories Limited

The main business activity of Unichem Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Unichem Laboratories Limited FY 2025-26 filings available

Unichem Laboratories Limited reported revenue of ₹2,201.85 Cr (up 4.3% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,202 Cr
+4.3% YoY
EBITDA
₹111 Cr
-58.3% YoY
Profit After Tax
₹81.89 Cr
-40.1% YoY
Net Worth
₹2,717 Cr
+10.9% YoY
Total Assets
₹3,247 Cr
+10.0% YoY
Total Debt
₹500 Cr
+8.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,2022,1111,7851,3431,2701,2351,104
Revenue growth+4.3%+18.3%+32.9%+5.8%+2.8%+11.9%-
EBITDA111265(38.74)(84.12)71.7290.77(50.82)
EBITDA margin+5.0%+12.6%-2.2%-6.3%+5.7%+7.4%-4.6%
Profit before tax292155(84.96)(176)21.9551.48(48.21)
Net profit81.89137(43.58)(178)31.5326.81(86.06)
Net profit margin+3.7%+6.5%-2.4%-13.3%+2.5%+2.2%-7.8%
EPS (₹)35.9119.53(13.32)(28.72)4.704.88(8.55)
Balance sheet
Total assets3,2472,9512,7222,7923,0122,7112,766
Net worth2,7172,4512,4382,4352,6182,5572,531
Total debt500460248314349119206
Cash & bank29511815818511482.45234
Net working capital1,7461,4111,1901,1861,078740889
Cash flow
Cash from operations3.64(7.02)14.00(85.09)(260)32.9819.82
Cash from investing194(242)63.31241100(65.97)(35.91)
Cash from financing1.86184(106)(81.30)191(121)(62.30)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue633575521579527587533507
Revenue growth (YoY)+20.1%-2.1%-2.2%+14.1%+9.0%---
Other income15.6123.4728720.976.829.2513.628.69
EBITDA69.9435.3244.787.9222.4983.7085.5255.49
EBITDA margin+11.1%+6.1%+8.6%+1.4%+4.3%+14.3%+16.0%+10.9%
Depreciation29.9430.6131.2531.4731.7929.6930.5432.26
Interest6.629.397.428.246.545.466.754.79
Profit before tax48.9918.79293(10.82)(9.02)57.8061.8527.13
Tax7.527.8829.141.071.454.834.002.50
Net profit41.4710.91264(11.89)(10.47)52.9757.8524.63
EPS (₹)5.891.5537.47(1.69)(1.49)7.508.193.49
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,4121,7361,4421,0729431,124904
Revenue growth-18.6%+20.4%+34.5%+13.7%-16.1%+24.3%-
EBITDA(23.30)254(74.71)(206)(43.55)95.48(90.61)
EBITDA margin-1.7%+14.6%-5.2%-19.2%-4.6%+8.5%-10.0%
Profit before tax209183(92.18)(279)(86.74)65.66(63.81)
Net profit(15.57)159(36.24)(197)(55.17)54.08(54.86)
Net profit margin-1.1%+9.1%-2.5%-18.3%-5.9%+4.8%-6.1%
EPS (₹)22.5823.15(13.09)(42.57)(7.87)7.68(8.00)
Balance sheet
Total assets2,7202,6212,4022,5362,8492,7342,692
Net worth2,6272,4602,2952,3842,6722,6972,647
Total debt64.0812370.301081321.4816.71
Cash & bank25888.6312915799.0357.59205
Net working capital1,2341,098943941837698753
Cash flow
Cash from operations52.6072.29(41.57)(117)(158)(32.61)(41.84)
Cash from investing210(176)59.61241104(72.79)(35.59)
Cash from financing(70.66)38.26(48.06)(61.76)95.80(45.07)(21.02)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue366356315357384461448437
Revenue growth (YoY)-4.7%-22.8%-29.7%-18.3%-1.4%---
Other income16.7222.2229121.404.2510.0518.937.08
Total expenses346356314382359386374372
EBITDA20.640.131.39(25.44)25.7474.9874.2164.50
EBITDA margin+5.6%+0.0%+0.4%-7.1%+6.7%+16.3%+16.6%+14.8%
Depreciation28.6928.9730.0230.1129.9327.4728.4526.39
Interest1.294.092.103.681.931.532.891.82
Profit before tax7.38(10.71)260(37.83)(1.87)56.0361.8043.37
Tax1.854.6843.712.10(0.02)4.8114.910.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue633575521579527587533507
Revenue growth (YoY)+20.1%-2.1%-2.2%+14.1%+9.0%---
Other income15.6123.4728720.976.829.2513.628.69
EBITDA69.9435.3244.787.9222.4983.7085.5255.49
EBITDA margin+11.1%+6.1%+8.6%+1.4%+4.3%+14.3%+16.0%+10.9%
Depreciation29.9430.6131.2531.4731.7929.6930.5432.26
Interest6.629.397.428.246.545.466.754.79
Profit before tax48.9918.79293(10.82)(9.02)57.8061.8527.13
Tax7.527.8829.141.071.454.834.002.50
Net profit41.4710.91264(11.89)(10.47)52.9757.8524.63
EPS (₹)5.891.5537.47(1.69)(1.49)7.508.193.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,2022,1111,7851,3431,2701,2351,104
Revenue growth+4.3%+18.3%+32.9%+5.8%+2.8%+11.9%-
Other income33935.3299.6038.5247.5150.1992.13
Total expenses2,0911,8461,8241,4271,1981,1441,155
Employee cost397402403356330307273
EBITDA111265(38.74)(84.12)71.7290.77(50.82)
EBITDA margin+5.0%+12.6%-2.2%-6.3%+5.7%+7.4%-4.6%
Depreciation12512512311391.1784.3681.67
Interest31.5921.0322.6617.316.115.127.85
Profit before tax292155(84.96)(176)21.9551.48(48.21)
Tax39.5417.078.8025.86(11.09)17.1511.97
Net profit81.89137(43.58)(178)31.5326.81(86.06)
Net profit margin+3.7%+6.5%-2.4%-13.3%+2.5%+2.2%-7.8%
EPS (₹)35.9119.53(13.32)(28.72)4.704.88(8.55)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.0814.0814.0814.0814.0814.0814.08
Reserves & surplus2,7032,4372,4242,4212,6042,5432,517
Shareholders' funds (net worth)2,7172,4512,4382,4352,6182,5572,531
Minority interest0.000.000.000.000.000.000.00
Secured loans469430219297330101184
Unsecured loans31.3729.8028.3716.6518.7918.4722.47
Total debt500460248314349119206
Total liabilities3,2472,9512,7222,7923,0122,7112,766
Assets
Gross block1,9851,9941,9201,7501,3801,1811,102
Net block1,2131,3001,2521,257990884870
Capital work in progress10030.67123147494568330
Investments0.020.021.361.70264392550
Inventories975989736625600538397
Sundry debtors829779642589495250390
Cash & bank balances29511815818511482.45234
Loans & advances99.09144205188175270247
Total current assets2,1972,0291,7421,5871,3851,1411,267
Total current liabilities451618552401307401379
Net working capital1,7461,4111,1901,1861,078740889
Total assets3,2472,9512,7222,7923,0122,7112,766
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash89.5815518410977.46232310
Net cash from operating activities3.64(7.02)14.00(85.09)(260)32.9819.82
Net cash from investing activities194(242)63.31241100(65.97)(35.91)
Net cash from financing activities1.86184(106)(81.30)191(121)(62.30)
Net change in cash200(65.17)(29.00)74.5631.74(154)(78.40)
Closing cash29511815818511482.45234
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.3%+18.3%+32.9%+5.8%+2.8%+11.9%-
EBITDA growth-58.3%+783.7%+54.0%-217.3%-21.0%+278.6%-
PBT growth+89.1%+9998.0%+51.8%--57.4%+9998.0%+17.1%
Net income growth-40.1%+413.6%+75.5%-665.2%+17.6%+131.2%-
Revenue CAGR (3Y)+17.9%+18.5%+13.1%+6.8%+2.5%+14.9%+16.5%
EBITDA CAGR (3Y)-+54.6%-+18.3%--+7.1%
Profitability & leverage
Net income margin+11.5%+6.5%-5.3%-15.1%+2.6%+2.8%-5.5%
Return on capital employed+4.1%+6.2%-0.2%-4.5%+0.9%+1.7%-2.4%
Return on net worth+3.2%+5.6%-1.8%-7.1%+1.2%+1.1%-3.3%
Debt / equity0.190.140.120.130.090.060.08
Long-term debt / equity0.030.030.030.040.020.010.00
Interest cover-216.2214.99-14.00-8.76-31.4179.88-5.92
Efficiency & per share
Fixed asset turnover1.111.080.970.861.001.081.06
Inventory turnover2.242.452.622.192.232.643.00
Debtors turnover2.742.972.902.483.413.862.67
EPS (₹)35.9119.53(13.32)(28.72)4.704.88(8.55)
Dividend per share (₹)0.000.000.004.004.004.004.00
Book value per share (₹)386.00348.10346.35345.89371.90363.16359.54
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue366356315357384461448437
Revenue growth (YoY)-4.7%-22.8%-29.7%-18.3%-1.4%---
Other income16.7222.2229121.404.2510.0518.937.08
Total expenses346356314382359386374372
EBITDA20.640.131.39(25.44)25.7474.9874.2164.50
EBITDA margin+5.6%+0.0%+0.4%-7.1%+6.7%+16.3%+16.6%+14.8%
Depreciation28.6928.9730.0230.1129.9327.4728.4526.39
Interest1.294.092.103.681.931.532.891.82
Profit before tax7.38(10.71)260(37.83)(1.87)56.0361.8043.37
Tax1.854.6843.712.10(0.02)4.8114.910.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,4121,7361,4421,0729431,124904
Revenue growth-18.6%+20.4%+34.5%+13.7%-16.1%+24.3%-
Other income36444.8398.4041.8542.0747.3799.17
Total expenses1,4361,4821,5171,2789861,028995
Employee cost277288283271251234205
EBITDA(23.30)254(74.71)(206)(43.55)95.48(90.61)
EBITDA margin-1.7%+14.6%-5.2%-19.2%-4.6%+8.5%-10.0%
Depreciation11910810510683.1975.8971.09
Interest11.807.6210.429.382.071.301.28
Profit before tax209183(92.18)(279)(86.74)65.66(63.81)
Tax50.4719.720.0020.61(31.32)11.56(7.50)
Net profit(15.57)159(36.24)(197)(55.17)54.08(54.86)
Net profit margin-1.1%+9.1%-2.5%-18.3%-5.9%+4.8%-6.1%
EPS (₹)22.5823.15(13.09)(42.57)(7.87)7.68(8.00)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.0814.0814.0814.0814.0814.0814.08
Reserves & surplus2,6132,4462,2812,3702,6582,6832,633
Shareholders' funds (net worth)2,6272,4602,2952,3842,6722,6972,647
Secured loans53.3411163.881021000.0015.21
Unsecured loans10.7411.656.426.5831.651.481.50
Total debt64.0812370.301081321.4816.71
Total liabilities2,7202,6212,4022,5362,8492,7342,692
Assets
Gross block1,9491,9261,7181,6911,3191,1281,039
Net block1,1891,2751,1651,236963850829
Capital work in progress10031.03122148494568331
Investments47.4945.6244.0840.51390520668
Inventories592584501480461386316
Sundry debtors583748558472381360323
Cash & bank balances25888.6312915799.0357.59205
Loans & advances100146195182170265242
Total current assets1,5341,5661,3831,2911,1101,0691,086
Total current liabilities300468440351273371333
Net working capital1,2341,098943941837698753
Total assets2,7202,6212,4022,5362,8492,7342,692
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash60.5812615694.1352.60203302
Net cash from operating activities52.6072.29(41.57)(117)(158)(32.61)(41.84)
Net cash from investing activities210(176)59.61241104(72.79)(35.59)
Net cash from financing activities(70.66)38.26(48.06)(61.76)95.80(45.07)(21.02)
Net change in cash192(65.07)(30.02)61.5441.53(150)(98.45)
Closing cash25888.6312915799.0357.59205
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-18.6%+20.4%+34.5%+13.7%-16.1%+24.3%-
EBITDA growth-109.2%+439.8%+63.7%-372.0%-145.6%+205.4%-
PBT growth+14.6%+9998.0%+67.0%-221.7%-+9998.0%-221.8%
Net income growth-109.8%+537.5%+81.6%-256.2%-202.0%+198.6%-
Revenue CAGR (3Y)+9.6%+22.6%+8.7%+5.8%-0.9%+19.1%+16.2%
EBITDA CAGR (3Y)-51.6%--+31.4%-10.5%-+16.0%
Profitability & leverage
Net income margin+11.3%+9.4%-6.4%-27.9%-5.9%+4.8%-6.2%
Return on capital employed-0.1%+7.6%-1.1%-5.9%-3.0%+2.5%-2.3%
Return on net worth-0.6%+6.9%-1.6%-7.8%-2.1%+2.0%-2.1%
Debt / equity0.040.040.040.050.020.000.00
Long-term debt / equity0.020.020.020.030.020.000.00
Interest cover-8.295.24-5.78-3.01-1.636.64-0.79
Efficiency & per share
Fixed asset turnover0.730.950.850.710.771.040.91
Inventory turnover2.403.202.942.282.233.203.07
Debtors turnover2.122.662.802.512.543.292.76
EPS (₹)22.5823.15(13.09)(42.57)(7.87)7.68(8.00)
Dividend per share (₹)0.000.000.004.004.004.004.00
Book value per share (₹)373.17349.40325.94338.65379.52383.11375.99
Want more history and ratios?
You're viewing the latest exchange-filed financials for Unichem Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Board of Directors of Unichem Laboratories Limited

Unichem Laboratories has 6 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Prakash Amrut Mody
Also directs: Elemage Wellness LLP, Prajay Advisors LLP, SPM International Private Limited
Director01 Jul 200818 Years 3 MonthsCurrent
Swati Arvind Patankar
Also directs: Ipca Laboratories Limited
Additional Director05 Feb 20260 Years 8 MonthsCurrent
Arun Lalchand Todarwal
Also directs: Arun Todarwal & Associates LLP, Arun Todarwal & Co LLP, Laxmi Organic Industries Limited and 5 more
Director05 Feb 20242 Years 8 MonthsCurrent
Anand Trimbak Kusre
Also directs: Entrepreneurship Development Center, Coep's Bhau Institute of Innovation Entrepreneurship and Leadership, Dharwad Research and Technology Incubator Foundation
Director05 Feb 20242 Years 8 MonthsCurrent
Pranay Premchand Godha
Also directs: Xgrow Traders LLP, Xbees Traders LLP, Ipca Laboratories Limited and 2 more
Director10 Aug 20233 Years 2 MonthsCurrent
Pabitrakumar Kalipada Bhattacharyya
Also directs: Krebs Biochemicals and Industries Limited
Managing Director10 Aug 20233 Years 2 MonthsCurrent
View all directors

Peer Comparison of Unichem Laboratories Limited

Unichem Laboratories Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Aarti Drugs Limited Listed₹2,403.39 Cr (FY 2025)••••••••-5.0%••••Thane, Maharashtra, India
Centrient Pharmaceuticals India Private Limited₹2,240.1 Cr (FY 2025)••••••••8.0%••••Toansa, Punjab, India
Marksans Pharma Limited Listed₹2,227.83 Cr (FY 2024)••••••••17.0%••••Mumbai, Maharashtra, India
Unichem Laboratories Limited this company₹2,201.85 Cr (FY 2026)••••••••4.3%••••Mumbai, Maharashtra, India
Merck Life Science Private Limited₹2,200.06 Cr (FY 2025)••••••••7.0%••••Mumbai, Maharashtra, India
FDC Limited Listed₹2,198.78 Cr (FY 2025)••••••••8.0%••••Mumbai, Maharashtra, India
Iol Chemicals and Pharmaceuticals Limited Listed₹2,101.62 Cr (FY 2025)••••••••-3.0%••••Barnala, Punjab, India
Tianish Laboratories Private Limited₹2,059.53 Cr (FY 2024)••••••••••••Hyderabad, Telangana, India
Caplin Point Laboratories Limited Listed₹2,033.9 Cr (FY 2025)••••••••15.0%••••Chennai, Tamil Nadu, India
Pfizer Healthcare India Private Limited₹1,981.45 Cr (FY 2025)••••••••4.0%••••Chennai, Tamil Nadu, India
MSN Life Sciences Private Limited₹1,961.87 Cr (FY 2024)••••••••54.0%••••Hyderabad, Telangana, India

Peers are the five companies nearest above and the five nearest below Unichem Laboratories by revenue in the Pharma industry (API Manufacturers, Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Unichem Laboratories Limited

Unichem Laboratories Limited is audited by N. A. Shah Associates LLP for the financial year 2025.

NameStatusAppointment DateCessation Date
N. A. Shah Associates LLPLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Shareholding Pattern of Unichem Laboratories Limited

Shareholding for the quarter ended Sep 2026: promoters hold 70.20%, foreign institutional investors hold 0.90%, domestic institutional investors hold 10.50% and retail and other public shareholders hold 18.40%.

Promoters: 70.20%DII (Domestic Institutional): 10.50%FII (Foreign Institutional): 0.90%Retail & Others: 18.40%
Sep 2026
QUARTER
70.20% Promoters
10.50% DII (Domestic Institutional)
0.90% FII (Foreign Institutional)
18.40% Retail & Others
Promoter holding - history
Now 70.20% · Sep 2026High 70.20% · Dec 2025Low 70.20% · Dec 2025
69%69.8%70.5%71.3%72%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 70.20%Mar 2026: 70.20%Jun 2026: 70.20%Sep 2026: 70.20%70.20%70.20%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters70.20%70.20%70.20%70.20%
Public29.80%29.80%29.80%29.80%

Charges & Borrowings of Unichem Laboratories Limited

Open charges
₹236 Cr
Satisfied charges
₹249.07 Cr
Breakdown by lending institutions
Others₹155.00 Cr
Citi Bank N.A.₹81.00 Cr
Latest charge details
DateLenderAmountStatus
20 Jun 2025Citi Bank N.A.₹30 CrOpen
24 Jan 2025Citi Bank N.A.₹51 CrOpen
04 Jan 2022Others₹30 CrOpen
31 May 2019Others₹125 CrOpen
28 Feb 2020Axis Bank Limited₹30 CrSatisfied

Total charge records: 54 View all charges

Deals & Funding of Unichem Laboratories Limited

Unichem Laboratories Limited has 14 deals on record (9 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹56.32 Cr; the latest was in July 2026.

Total deals
14
Market trades
9
Secondary share transfers
2
Acquisitions
2
Funding round
1
Disclosed funding
₹56.32 Cr

Deals on record (5 of 14)

WhenDealAmountParties
Jun 2026Market trade₹260.33 CrBuyer: NK Securities Research Private Limited , Junomoneta Finsol Private Limited , Microcurves Trading Private Limited
Seller: NK Securities Research Private Limited , Junomoneta Finsol Private Limited , Microcurves Trading Private Limited
Aug 2023Market trade₹945.35 CrBuyer: Ipca Laboratories Limited
Seller: an individual
Apr 2023Secondary share transferUndisclosedBuyer: Ipca Laboratories Limited
Seller: an individual
Feb 2018Market trade₹40.23 CrBuyer: SMC Global Securities Limited
Seller: Nordea 1 Sicav Indian Equity Fund N2239Lua, SMC Global Securities Limited
Nov 2017Acquisition₹3,600 CrBuyer: Torrent Pharmaceuticals Ltd
Seller: Unichem Laboratories Limited
Premium access

Full deal history

All 14 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Unichem Laboratories Limited

Unichem Laboratories Limited has 30 MSME Form 1 returns on record between 2014 and 2024, listing 197 overdue payments to 63 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 63)

SupplierAmount dueDue sinceReported on
an individual supplier••••••••••••
an individual supplier••••••••••••
an individual supplier••••••••••••
an individual supplier••••••••••••
FSP Technologies••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 30 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Unichem Laboratories Limited

Unichem Laboratories Limited has a workforce of 3,635 employees as of Sep 25, 2025.

Employee count
3,635
Active EPFO establishments
8
Employee growth
4.91%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of Unichem Laboratories Limited

Unichem Laboratories has 1 associated company. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.

1
Associated companies

Recent Activity on Unichem Laboratories Limited

Unichem Laboratories Limited has 30 board changes on record since 1979: 19 appointments and 11 cessations. The latest: Swati Arvind Patankar was appointed as Additional Director on 05 Feb 2026.

Appointed
Swati Arvind Patankar was appointed as Additional Director.
Charges
A charge with Others of Rs. 125.00 Cr registered on 31 May 2019 with Charge ID 100269504 was modified on 14 Jan 2026.
AGM
Unichem Laboratories Limited last Annual general meeting of members was held on 04 Aug 2025 as per latest MCA records.
Charges
A charge registered on 28 Feb 2020 via Charge ID 100327424 with Axis Bank Limited was fully satisfied on 17 Jul 2025.
Charges
A charge with Citi Bank N.A. amounted to Rs. 30.00 Cr with Charge ID 101119422 was registered on 20 Jun 2025.
Filing
Unichem Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
A charge with Citi Bank N.A. amounted to Rs. 51.00 Cr with Charge ID 101041700 was registered on 24 Jan 2025.
Charges
A charge registered on 16 Jul 2016 via Charge ID 100040728 with Bank Of India was fully satisfied on 07 Aug 2024.
Charges
A charge registered on 23 Jan 2018 via Charge ID 100154071 with Citi Bank N.A. was fully satisfied on 19 Jun 2024.
Ceased
Anand Yashavant Mahajan ceased to be Director.
Ceased
Prafulbhai Anubhai Shah ceased to be Director.
Ceased
Prafull D Sheth ceased to be Director.

147 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Unichem Laboratories Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Unichem Laboratories Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Unichem Laboratories Limited

Unichem Laboratories has 26 GST registrations: 6 active and 20 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
26
Active
6
Cancelled / inactive
20
GSTINStateStatusRegistered on
27AAACU0551B1ZWMaharashtraActive01 Jul 2017
27AAACU0551B2ZVMaharashtraActive21 Jul 2017
02AAACU0551B2Z7Himachal PradeshActive01 Jul 2017
09AAACU0551B1ZUUttar PradeshActive01 Jul 2017
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Unichem Laboratories Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Related news about Unichem Laboratories Limited

Unichem Laboratories: USFDA inspection at Goa formulation facility concludes with 5 observations related to procedural enhancements; co to respond within 15 days.
26 Sep 2026 · Exchange Update
Unichem Laboratories: Company Hit with ₹87.07 Crore CGST Penalty, Aims to Appeal Decision.
19 Sep 2026 · Exchange Update

Frequently Asked Questions about Unichem Laboratories Limited

Unichem Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 22 August 1962 (64+ years old) and is registered under CIN L99999MH1962PLC012451. Listed on BSE: 506690 and NSE: UNICHEMLAB.

Unichem Laboratories reported revenue of ₹2,201.85 Cr for FY 2025-26 (up 4.3% YoY) based on consolidated financials.

Unichem Laboratories has 6 current directors:

The GSTIN of Unichem Laboratories is 27AAACU0551B1ZW, registered in Maharashtra. The company has 26 GST registrations in all, of which 6 are active and 20 are cancelled or inactive. Other active GSTINs include 27AAACU0551B2ZV (Maharashtra), 02AAACU0551B2Z7 (Himachal Pradesh), 09AAACU0551B1ZU (Uttar Pradesh).

The CIN (Corporate Identification Number) of Unichem Laboratories is L99999MH1962PLC012451. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Unichem Laboratories is listed on both BSE (code: 506690) and NSE (symbol: UNICHEMLAB).

Unichem Laboratories has 245 court cases on record: 156 filed by the company and 72 filed against it. 40 are pending. Most are in the high courts.

Unichem Laboratories was incorporated on 22 August 1962, making it 64+ years old. It is registered with the Registrar of Companies, Mumbai.

Unichem Laboratories has 14 deals on record (9 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹56.32 Cr; the latest was in July 2026.

The peers of Unichem Laboratories by revenue are Aarti Drugs Limited, Centrient Pharmaceuticals India Private Limited, Marksans Pharma Limited, Merck Life Science Private Limited, FDC Limited and 5 more, all in the Pharma industry (API Manufacturers, Formulations).

Swati Arvind Patankar was appointed as Additional Director on 05 Feb 2026. Anand Yashavant Mahajan ceased to be Director on 31 Mar 2024. Prafulbhai Anubhai Shah ceased to be Director on 31 Mar 2024. Unichem Laboratories has 30 board changes on record in total.

Unichem Laboratories has 30 MSME Form 1 returns on record between 2014 and 2024, listing 197 overdue payments to 63 micro and small suppliers. The latest return was filed on 24 Apr 2024.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available